These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The efficacy of hydrotalcite compared with OTC famotidine in the on-demand treatment of gastroesophageal reflux disease: a non-inferiority trial. Konturek JW; Beneke M; Koppermann R; Petersen-Braun M; Weingärtner U Med Sci Monit; 2007 Jan; 13(1):CR44-9. PubMed ID: 17179910 [TBL] [Abstract][Full Text] [Related]
25. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group. Sabesin SM; Berlin RG; Humphries TJ; Bradstreet DC; Walton-Bowen KL; Zaidi S Arch Intern Med; 1991 Dec; 151(12):2394-400. PubMed ID: 1746996 [TBL] [Abstract][Full Text] [Related]
27. Comparisons of the distribution of oesophageal acid exposure throughout the sleep period among the different gastro-oesophageal reflux disease groups. Dickman R; Parthasarathy S; Malagon IB; Jones P; Han B; Powers J; Fass R Aliment Pharmacol Ther; 2007 Jul; 26(1):41-8. PubMed ID: 17555420 [TBL] [Abstract][Full Text] [Related]
28. [Role of 24 hour intraesophageal pH monitoring in diagnosis of gastroesophageal reflux and assessment of drug effectiveness]. Abidin ZU; Ivashkin VT; Sheptulin AA; Trukhmanov AS; Okhlobystin AV Klin Med (Mosk); 1999; 77(7):39-42. PubMed ID: 10483164 [TBL] [Abstract][Full Text] [Related]
29. Primary gastro-oesophageal reflux disease and irritable oesophagus syndrome as causes of recurrent abdominal pain in children. Corrado G; Cavaliere M; Frandina G; Rea P; Pacchiarotti C; Capocaccia P; Cardi E Ital J Gastroenterol; 1996; 28(8):462-9. PubMed ID: 9032590 [TBL] [Abstract][Full Text] [Related]
30. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial. Bautista J; Fullerton H; Briseno M; Cui H; Fass R Aliment Pharmacol Ther; 2004 May; 19(10):1123-30. PubMed ID: 15142202 [TBL] [Abstract][Full Text] [Related]
31. Gastro-oesophageal reflux disease in Sudan: a clinical endoscopic and histopathological study. Ahmed HH; Mudawi HM; Fedail SS Trop Gastroenterol; 2004; 25(3):135-8. PubMed ID: 15682661 [TBL] [Abstract][Full Text] [Related]
32. The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease. Hatlebakk JG; Johnsson F; Vilien M; Carling L; Wetterhus S; Thøgersen T Scand J Gastroenterol; 1997 Nov; 32(11):1100-6. PubMed ID: 9399390 [TBL] [Abstract][Full Text] [Related]
33. Heartburn and gastro-oesophageal reflux. Bennett JR Br J Clin Pract; 1991; 45(4):273-7. PubMed ID: 1810362 [TBL] [Abstract][Full Text] [Related]
35. Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis. Hamamoto N; Hashimoto T; Adachi K; Hirakawa K; Ishihara S; Inoue H; Taniura H; Niigaki M; Sato S; Kushiyama Y; Suetsugu H; Miyake T; Kinoshita Y J Gastroenterol Hepatol; 2005 Feb; 20(2):281-6. PubMed ID: 15683433 [TBL] [Abstract][Full Text] [Related]
36. [Peptic complications of gastroesophageal reflux in children. Apropos of 62 cases]. Chaouachi B; Ben Salah S; Helioui S; Lakhoua R; Saied H Pediatrie; 1988; 43(3):251-6. PubMed ID: 3194164 [TBL] [Abstract][Full Text] [Related]
37. Treatment of childhood peptic oesophagitis with famotidine or alginate-antacid. Oderda G; Dell'Olio D; Forni M; Farina L; Tavassoli K; Ansaldi N Ital J Gastroenterol; 1990 Dec; 22(6):346-9. PubMed ID: 2131953 [TBL] [Abstract][Full Text] [Related]
38. Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis. Simon TJ; Berenson MM; Berlin RG; Snapinn S; Cagliola A Aliment Pharmacol Ther; 1994 Feb; 8(1):71-9. PubMed ID: 8186349 [TBL] [Abstract][Full Text] [Related]
39. Endoscopic appearance of GERD: putative role of cell proliferation. Calabrese C; Trerè D; Fabbri A; Cenacchi G; Vici M; Derenzini M; Di Febo G Dig Liver Dis; 2007 Aug; 39(8):713-9. PubMed ID: 17606421 [TBL] [Abstract][Full Text] [Related]
40. Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitis. Simon TJ; Roberts WG; Berlin RG; Hayden LJ; Berman RS; Reagan JE Clin Ther; 1995; 17(6):1147-56. PubMed ID: 8750406 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]